Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Completed 2Active not recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Dermatologic 3Gastrointestinal 2Gynecologic 1Genitourinary 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 35Stomach Neoplasms 34Lung Neoplasms 13Neoplasms 12Adenocarcinoma 11Neoplasm Metastasis 10Colorectal Neoplasms 9Esophageal Neoplasms 7Carcinoma, Hepatocellular 7Colonic Neoplasms 5Carcinoma, Renal Cell 5Breast Neoplasms 5Adenocarcinoma Of Esophagus 5Urinary Bladder Neoplasms 3Urethral Neoplasms 3Rectal Neoplasms 3Melanoma 3Liver Neoplasms 3Carcinoma, Transitional Cell 3Biliary Tract Neoplasms 3Ureteral Neoplasms 2Thymoma 2Squamous Cell Carcinoma of Head and Neck 2Solid Tumors 2Sarcoma 2Recurrence 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Non-small Cell Lung Cancer Metastatic 2Metastatic Gastric Adenocarcinoma 2

Interventions

pembrolizumab 287Nivolumab 258Ipilimumab 236Cyclophosphamide 135aldesleukin 134Interleukin-2 104Temozolomide 75Dacarbazine 74trametinib 70Vemurafenib 69fludarabine 68dabrafenib 65fludarabine phosphate 62sargramostim 44binimetinib 44Radiosurgery 44Biopsy 43Paclitaxel 42Bevacizumab 42incomplete Freund's adjuvant 39encorafenib 37Radiotherapy 36Cisplatin 36CTLA-4 Antigen 36atezolizumab 35Carboplatin 35Magnetic Resonance Spectroscopy 33cobimetinib 32Specimen Handling 31Introns 30

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Melanoma × Ramucirumab × Clear all
NCT03872947 2025-08-03

A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors

Toray Industries, Inc

Phase 1 Active not recruiting
138 enrolled
DermatologicGastrointestinalGenitourinaryGynecologic

Carcinoma, Ovarian Epithelial, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Fallopian Tube Neoplasms, Melanoma, Ovarian Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT02791334 2024-09-27

PACT

Eli Lilly and Company

Phase 1 Completed
164 enrolled
BreastDermatologicGastrointestinal

Breast Neoplasms, Melanoma, Pancreatic Neoplasms

NCT00533702 2014-08-01

A Study of IMC-1121B (Ramucirumab) With or Without Dacarbazine in Metastatic Malignant Melanoma

Eli Lilly and Company

Phase 2 Completed
106 enrolled 15 charts
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡